The aim of this study is to evaluate the efficacy and safety of Chantix as a means of reducing smoking rates in patients following Acute Coronary Syndrome. All study related testing will be completed at no cost to the patient. Compensation may occur for qualified patients.
- Patient Population – Patients who have recently suffered a heart attack and are active smokers. Patients must be motivated to quit smoking and currently smoke greater than or equal to 10 cigarettes per day.
- Sponsor – St. Michael's Hospital ; Sunnybrook Health Sciences Centre ; Queen Elizabeth II Health Sciences Centre ; Jewish General Hospital
- Contact Information – (402) 384 – 2705, MPCHeartConsultantsResearch@nmhs.org
- Clinical Trials Government Link
This Study Is Closed To Enrollment.